BackDicerna Pharmaceuticals Overview

Dicerna Pharmaceuticals Other Assets

Dicerna Pharmaceuticals's other assets is $0.

Get informed when a big investor buys or sells

+ Follow
Other Assets
$0.00

Peer trimmed avg / median

Loading

Dicerna Pharmaceuticals Other Assets History

Loading

Dicerna Pharmaceuticals vs. peers: Other Assets Comparison

Loading

Dicerna Pharmaceuticals Other Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Dicerna Pharmaceuticals (DRNA) FAQ

As of the most recent data (September 2021), DRNA shows a other assets of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, DRNA's other assets is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Dicerna Pharmaceuticals is outperforming or lagging.

Tracking DRNA's other assets over time shows whether Dicerna Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other assets page, Stockcircle has Dicerna Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other assets (currently $0) with ownership activity and broader fundamentals.

Dicerna Pharmaceuticals's other assets is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.